BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 35015186)

  • 1. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.
    Michaeli DT; Michaeli JC; Boch T; Michaeli T
    Cardiovasc Drugs Ther; 2023 Aug; 37(4):683-694. PubMed ID: 35015186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
    Michaeli DT; Michaeli JC; Boch T; Michaeli T
    Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
    Ademi Z; Ofori-Asenso R; Zomer E; Owen A; Liew D
    Eur J Prev Cardiol; 2021 Jul; 28(8):897-904. PubMed ID: 34298556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
    Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
    Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
    Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults.
    Xiang Y; Gan L; Du H; Hao Q; Aertgeerts B; Li S; Hu M
    Int J Technol Assess Health Care; 2023 Aug; 39(1):e53. PubMed ID: 37650314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia - An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS).
    Kodera S; Morita H; Kiyosue A; Ando J; Komuro I
    Circ J; 2018 Mar; 82(4):1076-1082. PubMed ID: 29367520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
    Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
    Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
    Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
    Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan.
    Kodera S; Morita H; Kiyosue A; Ando J; Takura T; Komuro I
    Circ J; 2018 Sep; 82(10):2602-2608. PubMed ID: 30033948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
    Gao L; Moodie M; Li SC
    Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
    Kazi DS; Penko J; Coxson PG; Guzman D; Wei PC; Bibbins-Domingo K
    Ann Intern Med; 2019 Feb; 170(4):221-229. PubMed ID: 30597485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis.
    Yang H; Li N; Zhou Y; Xiao Z; Tian H; Hu M; Li S
    Drug Des Devel Ther; 2020; 14():157-165. PubMed ID: 32021100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
    Abushanab D; Al-Badriyeh D; Marquina C; Bailey C; Jaam M; Liew D; Ademi Z
    Curr Probl Cardiol; 2023 Aug; 48(8):101211. PubMed ID: 35460688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
    Davies GM; Vyas A; Baxter CA
    J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification.
    Marquina C; Morton J; Zomer E; Talic S; Lybrand S; Thomson D; Liew D; Ademi Z
    Value Health; 2023 Apr; 26(4):498-507. PubMed ID: 36442832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.